Phase 2 N=130 Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.
Multiple Myeloma
Primary: Phase I - Maximum Tolerated Dose (MTD) Level — 127.8; 30 mg/m^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=167 Pharmacokinetics/Pharmacodynamics of Albiglutide
Diabetes Mellitus, Type 2
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to Infinity (0-inf) of Albiglutide in the Bioequivalence (BE) Phase — 496190.200; 464985.355…
Phase 1 N=11 Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium
Asthma · Perennial Allergic Rhinitis
Primary: Number of Reported Treatment-related Adverse Events (AEs) — 0; 0; 0; 0 Events
Phase 3 N=582 A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Type 2 Diabetes
Primary: Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure for 12 Week Double-Blind Treatment Period - Randomized Participants — -5.13; -7.93; -6.05; -9.69…
Phase 4 N=146 Herniectomy Versus Herniectomy With a Spinal Stabilization System for the Treatment of Complex Disc Disease
Sciatica · Back Pain
Primary: To Demonstrate a Statistically Significant Difference in the Relief of Back Pain Between Both Treatment Groups. The Endpoint Will be the Difference Between Baseline and…
Phase 4 N=5 Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)
Knee Pain After Total Knee Arthroplasty · Osteoarthritis Pain
Primary: Change in Pain Visual Analogue Scale(VAS). — 44 units on a scale
Phase 2 N=76 A School Program for Children Exposed to Violence
Stress Disorders, Post-Traumatic · Depression
Primary: Post-traumatic Stress Disorder Symptoms — 17.46; 19.41; 13.72; 18.32 units on a scale
N/A N=225 Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic GI Disorders
Irritable Bowel Syndrome · Colitis, Ulcerative · Crohn Disease
Primary: Colonic-Mucosa Associated Microbial Species Per Compiled Participants in 5 Different Arms — 40; 30; 23; 23 microbial species population
Phase 4 N=125 Quality of Life Intermittent Catheter Study
Neurogenic Bladder Dysfunction Nos
Primary: Quality of Life (0-100 Point) — 76.8; 59.8 units on a scale
Phase 4 N=8 Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetraplegia
Insomnia · Spinal Cord Injury · Tetraplegia
Primary: Amount of Wakefulness After Sleep Onset (WASO) — 72.3; 76.5 Minutes — p=0.70
Phase 2 N=326 High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
Influenza · Avian Influenza · Severe Influenza
Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42
N/A N=132 Study to Compare Survival for ASTRA TECH Implant System, OsseoSpeed™ Implants Following Immediate Loading in Extraction Sockets Versus Immediate Loading in Healed Ridges
Jaw, Edentulous, Partially
Primary: Implant Survival — 94.55; 98.28; 94.73 percentage of implants
Phase 3 N=54 Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old
Herpes Labialis
Primary: Reporting of Adverse Events — 9 participants
N/A N=20 Image Quality and Radiation Dose in Angiography
Arteriovenous Malformations · Aneurysm · Stenosis
Primary: Image Quality. For Each Included Participant 2 Images (1 AlluraXper; 1 AlluraClarity) Were Evaluated. — 9.4; 11.9; 13.1; 14.1 Scores on a scale
Phase 1 N=25 Effect of Delivery Route on PK of Sufentanil NanoTab
Pharmacokinetics
Primary: AUC (0 - Inf) — 273.8; 212.5; 163.4; 24.9 h.pg/mL